Behandling af neuroendokrine gastrointestinale tumorer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Behandling af neuroendokrine gastrointestinale tumorer. / Hansen, Carsten Palnaes; Langer, Seppo; Frevert, Susanne; Mortensen, Jann; Kjaer, Andreas; Knigge, Ulrich.
I: Ugeskrift for Laeger, Bind 172, Nr. 43, 25.10.2010, s. 2942-5.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Behandling af neuroendokrine gastrointestinale tumorer
AU - Hansen, Carsten Palnaes
AU - Langer, Seppo
AU - Frevert, Susanne
AU - Mortensen, Jann
AU - Kjaer, Andreas
AU - Knigge, Ulrich
PY - 2010/10/25
Y1 - 2010/10/25
N2 - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.
AB - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.
KW - Antineoplastic Agents/therapeutic use
KW - Combined Modality Therapy
KW - Gastrointestinal Neoplasms/drug therapy
KW - Humans
KW - Liver Neoplasms/secondary
KW - Neuroendocrine Tumors/drug therapy
KW - Palliative Care
KW - Pancreatic Neoplasms/drug therapy
KW - Practice Guidelines as Topic
KW - Prognosis
M3 - Tidsskriftartikel
C2 - 21040671
VL - 172
SP - 2942
EP - 2945
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 43
ER -
ID: 248232102